GRI BIO INC (GRI) Stock Price, Quote, News and Overview
NASDAQ:GRI - Nasdaq - US3622AW4030 - Common Stock - Currency: USD
GRI Quote, Performance and Key Statistics
NASDAQ:GRI (5/5/2025, 2:38:04 PM)
2.15
+0.05 (+2.38%)
The current stock price of GRI is 2.15 USD. In the past month the price increased by 45.83%. In the past year, price decreased by -97.68%.
GRI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.07 | 346.51B | ||
| AMGN | AMGEN INC | 13.45 | 150.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1735.17 | 129.36B | ||
| GILD | GILEAD SCIENCES INC | 13.3 | 128.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.75 | 65.78B | ||
| ARGX | ARGENX SE - ADR | 344.55 | 39.97B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.36B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.48B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.33B | ||
| NTRA | NATERA INC | N/A | 21.51B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.78B | ||
| BIIB | BIOGEN INC | 7.75 | 17.96B |
Related stock screener links
About GRI
Company Profile
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. The company is headquartered in La Jolla, California and currently employs 3 full-time employees. The company went IPO on 2021-02-10. The firm is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The firm is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).
Company Info
GRI BIO INC
2223 Avenida De La Playa, Suite 208
La Jolla CALIFORNIA US
Employees: 3
Phone: 16194001171
GRI BIO INC / GRI FAQ
What is the stock price of GRI BIO INC today?
The current stock price of GRI is 2.15 USD. The price increased by 2.38% in the last trading session.
What is the ticker symbol for GRI BIO INC stock?
The exchange symbol of GRI BIO INC is GRI and it is listed on the Nasdaq exchange.
On which exchange is GRI stock listed?
GRI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GRI BIO INC stock?
6 analysts have analysed GRI and the average price target is 199.41 USD. This implies a price increase of 9174.88% is expected in the next year compared to the current price of 2.15. Check the GRI BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GRI BIO INC worth?
GRI BIO INC (GRI) has a market capitalization of 1.14M USD. This makes GRI a Nano Cap stock.
How many employees does GRI BIO INC have?
GRI BIO INC (GRI) currently has 3 employees.
What are the support and resistance levels for GRI BIO INC (GRI) stock?
GRI BIO INC (GRI) has a support level at 1.72. Check the full technical report for a detailed analysis of GRI support and resistance levels.
Should I buy GRI BIO INC (GRI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GRI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GRI, evaluating the profitability, health, valuation and growth aspects
- GRI BIO INC (GRI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GRI BIO INC (GRI) Sales and EPS estimates to see what analysts future expectations are.
- GRI BIO INC (GRI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GRI BIO INC (GRI) Insider and Institutional Ownership to learn about the owners and their transactions.
- GRI BIO INC (GRI) Stock Chart to make your own analysis
- GRI BIO INC (GRI) Latest news and press-releases to stay up to date.
Does GRI BIO INC (GRI) stock pay dividends?
GRI does not pay a dividend.
When does GRI BIO INC (GRI) report earnings?
GRI BIO INC (GRI) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of GRI BIO INC (GRI)?
GRI BIO INC (GRI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-103.3).
What is the Short Interest ratio of GRI BIO INC (GRI) stock?
The outstanding short interest for GRI BIO INC (GRI) is 48.38% of its float. Check the ownership tab for more information on the GRI short interest.
GRI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GRI. When comparing the yearly performance of all stocks, GRI is a bad performer in the overall market: 99.57% of all stocks are doing better.
GRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GRI. GRI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GRI Financial Highlights
Over the last trailing twelve months GRI reported a non-GAAP Earnings per Share(EPS) of -103.3. The EPS decreased by -206.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -176.32% | ||
| ROE | -250.97% | ||
| Debt/Equity | 0 |
GRI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to GRI. The Buy consensus is the average rating of analysts ratings from 6 analysts.